Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Plasma cell 2Breast 2Other hematologic neoplasm 1Genitourinary 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteoporosis 2Myelodysplastic Syndromes 2Multiple Myeloma 2Hematologic Neoplasms 2Spinal Cord Compression 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Paraproteinemias 1Ovarian Neoplasms 1Osteosarcoma 1Osteonecrosis 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hodgkin Disease 1Hematologic Diseases 1Fractures, Bone 1Bone Neoplasms 1Bone Marrow Diseases 1Bone Diseases 1Blood Protein Disorders 1

Interventions

Zoledronic Acid 1Denosumab 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Diseases × Zoledronic Acid × Other hematologic neoplasm × Clear all
NCT01345019 2022-11-08

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Amgen

Phase 3 Completed
1,718 enrolled 22 charts
Other hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, Bone Neoplasms, Hematologic Diseases, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Paraproteinemias, Spinal Cord Compression, Hematologic Neoplasms, Fractures, Bone, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡